Neurocrine Biosciences, Inc.

Good day, everyone, and welcome to today's Neurocrine Biosciences third quarter 2025 results call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star 1 on your telephone keypad. Please note this call is being recorded. I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla.

Hi, everybody, and a very pleasant good afternoon to you, wherever you may be. Welcome to Neurocurrent Biosciences' third quarter 2025 earnings call. I'm joined today by Kyle Gaino, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, and Sanjay Kaswani, Chief Medical Officer. During our call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks and as is our standard practice, we will try to address all your questions. With that, I turn the call over to Kyle. Thank you, Todd.

Good afternoon, everyone. Our third quarter results reflect Neurocrin's exceptional execution and the strength of our enterprise-wide momentum as we continue to deliver across our commercial, clinical, and operational objectives. From a commercial perspective, for Ingresa, the recent investments to expand our sales force and improve patient access drove yet another record quarter for both new patient starts and total prescriptions, highlighting the persistent unmet need for patients with tardive dyskinesia in Huntington's, Korea. With chronicity, the strong launch highlights its role as a first-in-class therapy, redefining the standard of care for patients with classical congenital adrenal hyperplasia, or CH. While there is still much to learn, we are encouraged by the early response from the CH community and the potential to make a lasting impact for patients. Momentum for both Ingresa and Chronicity is strong, and we believe continued targeted investments in these commercial assets will accelerate growth into 2026 and beyond. In our clinical portfolio, I am pleased with the steady enrollment progress in our Phase III studies of Osteoamphator and major depressive disorder and directly dealing with schizophrenia. We remain on track to meet our enrollment objectives for the year. Beyond these late-stage programs, we continue to advance a robust early- and mid-stage that is expanding through high-quality preclinical programs emerging from Neurocrin's internal discovery efforts. To this end, I'm also happy to report that we are on track to achieve our R&D productivity goals for the year, specifically four new Phase I study initiations and two new Phase II initiations. Advancing two potentially standard of care changing medicines until their final phase of development, while simultaneously driving early and mid-stage innovation, represents a record level of productivity for us and positions Neurocrine exceptionally well for the future. As I reflect on my more than 20 years at Neurocrine and just over one year as CEO, I'm deeply proud of how far we've come. Yet, as we continue to evolve, I'm even more inspired by what lies ahead. Neurocrin is poised into our new chapter of sustained long-term growth driven by our science, our people, and our unwavering commitment to the patients we serve and the investors who support our mission. With that, I'll turn the call over to Matt.